9G2 — Singapore Institute of Advanced Medicine Holdings Income Statement
0.000.00%
- SG$36.21m
- SG$82.31m
- SG$15.72m
Annual income statement for Singapore Institute of Advanced Medicine Holdings, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 13.8 | 16.2 | 16.6 | 15.7 | 15.7 |
| Cost of Revenue | |||||
| Gross Profit | 12.6 | 15 | 15.4 | 14.4 | 14.5 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 28.2 | 30.5 | 37.9 | 40.6 | 36.1 |
| Operating Profit | -14.4 | -14.3 | -21.2 | -24.9 | -20.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.5 | -19 | -37.4 | -27 | -23.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.5 | -19 | -37.4 | -27 | -23.9 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -12.4 | -18.1 | -37.4 | -27.1 | -23.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.4 | -18.1 | -37.4 | -27.1 | -23.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.013 | -0.017 | -0.043 | -0.022 | -0.02 |